Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Read the highlights for the 2026 World Alzheimer's Month campaign, from ADI member activities to key events and achievements from the wider community of advocates united under the theme of ‘The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters’.
ADI announces our new CEO, joining on 1 October 2026
Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.
In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.
The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.
ADI, alongside Newcastle University and the London School of Economics, is submitting an application to the WHO Expert Committee on the inclusion of anti-dementia medication and needs to hear from clinicians everywhere.
The project, launching 1 September, will aim to raise funds for ADI through the sale of a collection of photographs in the form of NFTs.